A larger data set observed hair loss among dieters losing 8 or more pounds per month, with women and the elderly being at higher risk of telogen effluvium
Successful appeals require: A Letter of Medical Necessity from the prescribing provider that specifically addresses why tirzepatide is medically necessary for this patient, why alternative treatments are inadequate, and how the patient meets the payer clinical criteria
Analysis First, we described patient characteristics, overall and for GLP-1RA and SGLT-2i users (see Table 1)
Dosage and bioavailability are paramount
From this adjacent literature, a picture emerges of additive glucose-lowering effects, additive GLP-1 axis stimulation, and additive GI burden
Follow-up extended 6 to 12 months with sustained benefits reported